FWIW, I think the Board reached the right result, but needed to provide a better explanation of its ruling
1530 passed the House by a unanimous vote of 423-0
An intervention to stop smoking among patients suspected of TB: evaluation of an integrated approach
The current standard for drug-sensitive TB (DS-TB) is a 6-month regimen comprising isoniazid (INH), rifampin (also known as rifampicin) (RIF), pyrazinamide (PZA), and ethambutol (EMB), starting with a 2-month intensive phase of all four drugs, followed by 4 months of INH and RIF (Nyangwa et al., 2022), led to the introduction of 69 months regimens of bedaquiline, pretomanid, linezolid, with or without moxifloxacin (BPaL-M or BPaL, respectively), offering improved outcomes compared to older treatment strategies ( On this ground the WHO updated its DR-TB treatment guidelines in 2022 (WHO Consolidated Guidelines on Tuberculosis, 2024), recommending the 6-month BPaL-M regimen for MDR/Rifampicin-Resistant (RR)-TB in patients unexposed to bedaquiline, pretomanid, or linezolid (Vanino et al., 2023)
(Ausschnittscan Teil 1), (Ausschnittscan Teil 2) Webseite zum Weltkriegs-Werbeplakat der Eckstein-Marke Da Capo "BrandEckstein No5 - Cigarettes Pedia"
